drugset / Trial / NCT00965848

A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections

NCT00965848

Phase 4 Completed 270 enrolled Janssen-Cilag Ltd.,Thailand
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after hospital admission), complicated intra-abdominal (in belly) infections and complicated urinary tract infections (bladder infections).

Timeline

Start
2009-06
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Doripenem Small molecule 500 mg Intravenous